2011至2017年血管内卒中治疗趋势显示临床与经济结局显著改善
该回顾性观察研究基于Premier医疗数据库,纳入2011至2017年接受血管内治疗的急性缺血性卒中患者,分析住院时长、出院状态和费用的趋势。结果显示回家出院比例显著增加,死亡率显著下降,住院时长和总费用显著降低。
要点
- 血管内治疗患者回家出院比例从17.7%升至29.6%,死亡率从21.6%降至12.8%。
- 住院时长从11.7天降至8.7天,总住院费用下降约17%。
- 2011至2017年血管内治疗的临床与经济指标均显著改善。
核心结论
- 2011至2017年接受血管内治疗的急性缺血性卒中患者临床与经济指标显著改善。
研究设计与样本
- 采用Mann-Kendall趋势检验分析临床与经济结局趋势。
主要发现
- 接受血管内治疗的患者回家出院比例从17.7%显著增加至29.6%(P<0.01)。
- 死亡率从21.6%显著下降至12.8%(P<0.01)。
- 住院时长从11.7天显著下降至8.7天(P<0.01)。
临床怎么用
- 血管内治疗在急性缺血性卒中中的应用与临床和经济结局改善相关,支持其临床应用价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- The purpose of this study was to evaluate trends in length of stay, discharge status, and costs among patients with acute ischemic stroke who underwent endovascular therapy (ET) between 2011 and 2017. Methods- Using a retrospective observational study design, acute ischemic stroke patients undergoing ET from 2011 to 2017 were identified in the Premier Healthcare Database. The Mann-Kendall trend test was performed to examine clinical and economic outcomes trends. Results- Among the 505 824 acute ischemic stroke patients, 11 811(2.3%) were treated with ET. Patients receiving ET had a significant increase in home discharge and a significant decrease in mortality (17.7% to 29.6%, P<0.01; 21.6% to 12.8%, P<0.01). There was a significant decline in length of stay from 11.7 days to 8.7 days ( P<0.01). Total index admission costs declined ≈17% from 2011 to 2017 ($50 516.5-$42 026.9, P<0.01). Conclusions- Clinical and economic indicators significantly improved for acute ischemic stroke patients undergoing ET from 2011 to 2017.
引用
- Rai AT, Crivera C, Kalsekar I, et al. Endovascular Stroke Therapy Trends From 2011 to 2017 Show Significant Improvement in Clinical and Economic Outcomes. Stroke. 2019. PMID: 31104618. doi:10.1161/STROKEAHA.119.025112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。